Monopar Therapeutics Inc ( (MNPR) ) has shared an announcement.
Monopar Therapeutics Inc. announced the termination of Karthik Radhakrishnan’s employment as Chief Financial Officer, principal financial officer, and principal accounting officer on February 28, 2025. The company’s Board of Directors appointed Quan Vu as the new CFO, effective March 3, 2025. Vu brings extensive experience in corporate and financial strategy, having previously served in various leadership roles in the biopharmaceutical and investment banking sectors. This leadership change is expected to impact Monopar’s financial strategy and operations positively.
More about Monopar Therapeutics Inc
YTD Price Performance: 58.01%
Average Trading Volume: 71,024
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $214.3M
Learn more about MNPR stock on TipRanks’ Stock Analysis page.